ArticleThe journal of allergy and clinical immunology. In practice
Exploring the Utility of Noninvasive Type 2 Inflammatory Markers for Prediction of Severe Asthma Exacerbations in Children and Adolescents.
Article in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Biologic Therapies and Quality of Life in Pediatric Patients with Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Using mHealth to Predict Asthma Exacerbations in Children and Adolescents (Mobile Health for Kids With Asthma): Protocol for an Observational Study.JMIR research protocols · 2025Article
- Asthma Phenotypes and Biomarkers.Respiratory care · 2025Review
- Clinical and inflammatory features of traffic-related diesel exposure in children with asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Article
- Distinguishing Childhood Asthma Exacerbations from Stable Asthma: The Utility of Inflammatory White Blood Cell Biomarkers.Diagnostics (Basel, Switzerland) · 2024Article
- New targets for type 2-low asthma.The Korean journal of internal medicine · 2024Review
- Blood Eosinophils for Prediction of Exacerbation in Preschool Children With Recurrent Wheezing.The journal of allergy and clinical immunology. In practice · 2023Article
- Cluster analysis of plasma cytokines identifies two unique endotypes of children with asthma in the pediatric intensive care unit.Scientific reports · 2023Article
- Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.Annals of medicine · 2022Article
- Treating severe asthma: Targeting the IL-5 pathway.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Review
- Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.The journal of allergy and clinical immunology. In practice · 2021Article
- Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies.Allergy, asthma & immunology research · 2021Review
- The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations.International journal of molecular sciences · 2021Review
- Identification and treatment of T2-low asthma in the era of biologics.ERJ open research · 2021Review
- Pediatric Asthma Exacerbation in Children with Suspected and Confirmed Coronavirus Disease 2019 (COVID-19): An Observational Study from Saudi Arabia.Journal of asthma and allergy · 2021Article
- Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice.Breathe (Sheffield, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNoninvasive markers of type 2 inflammation are needed to identify children and adolescents who might benefit from personalized biologic therapy.
objectiveWe hypothesized that blood eosinophil counts would predict 1 or more acute visits for asthma and that prediction could be improved with the addition of a second, noninvasive type 2 inflammatory biomarker.
methodsChildren and adolescents 5 to 21 years (N = 589) with an asthma exacerbation necessitating systemic corticosteroid treatment in the previous year completed a characterization visit and telephone calls at 6 and 12 months. The primary outcome was an acute visit for asthma with receipt of systemic corticosteroids. Acute visits were verified by medical record review. Exploratory outcomes included time to first acute visit and hospitalization.
resultsAcute visits occurred in 106 (35.5%) children and 72 (24.8%) adolescents. Elevated blood eosinophils were associated with increased odds and shorter time to first acute visit, but optimal cut-points differed by age (≥150 vs ≥300 cells/μL for children vs adolescents, respectively). The addition of a second marker of type 2 inflammation did not improve prediction in children, but increased the odds and hazard of an acute visit up to 16.2% and 11.9%, respectively, in adolescents. Similar trends were noted for hospitalizations.
conclusionsBlood eosinophils and other noninvasive markers of type 2 inflammation may be useful in the clinical assessment of children and adolescents with asthma. However, features of type 2 inflammation vary by age. Whether children and adolescents also respond differently to management of type 2 inflammation is unclear and warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.